KR102062416B1 - 실용 가능한 암 진단 대체 법 - Google Patents

실용 가능한 암 진단 대체 법 Download PDF

Info

Publication number
KR102062416B1
KR102062416B1 KR1020147034524A KR20147034524A KR102062416B1 KR 102062416 B1 KR102062416 B1 KR 102062416B1 KR 1020147034524 A KR1020147034524 A KR 1020147034524A KR 20147034524 A KR20147034524 A KR 20147034524A KR 102062416 B1 KR102062416 B1 KR 102062416B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
patient
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147034524A
Other languages
English (en)
Korean (ko)
Other versions
KR20150008177A (ko
Inventor
윌리엄 피어스올
마이클 에이치. 카돈
Original Assignee
유트로픽스 파마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유트로픽스 파마슈티컬스, 인크. filed Critical 유트로픽스 파마슈티컬스, 인크.
Publication of KR20150008177A publication Critical patent/KR20150008177A/ko
Application granted granted Critical
Publication of KR102062416B1 publication Critical patent/KR102062416B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
KR1020147034524A 2012-05-10 2013-05-10 실용 가능한 암 진단 대체 법 Expired - Fee Related KR102062416B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645253P 2012-05-10 2012-05-10
US61/645,253 2012-05-10
US201361780252P 2013-03-13 2013-03-13
US61/780,252 2013-03-13
PCT/US2013/040585 WO2013170176A2 (en) 2012-05-10 2013-05-10 Surrogate functional diagnostics test for cancer

Publications (2)

Publication Number Publication Date
KR20150008177A KR20150008177A (ko) 2015-01-21
KR102062416B1 true KR102062416B1 (ko) 2020-01-03

Family

ID=49551473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147034524A Expired - Fee Related KR102062416B1 (ko) 2012-05-10 2013-05-10 실용 가능한 암 진단 대체 법

Country Status (6)

Country Link
US (2) US20150301053A1 (https=)
EP (2) EP2847592A4 (https=)
JP (2) JP2015519565A (https=)
KR (1) KR102062416B1 (https=)
CN (3) CN111856013A (https=)
WO (1) WO2013170176A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
WO2015010094A1 (en) * 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
US20180100859A1 (en) * 2015-03-24 2018-04-12 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
US9901574B2 (en) * 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016253957C1 (en) * 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
CN105653896B (zh) * 2016-01-22 2019-02-12 北京圣谷同创科技发展有限公司 高通量测序突变检测结果验证方法
EP3273240A1 (en) * 2016-07-17 2018-01-24 Mitogro OÜ Method for selecting patients responsive for cancer treatments
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
US20180293352A1 (en) * 2017-04-10 2018-10-11 COTA, Inc. System and Method for Decision-Making for Determining Initiation and Type of Treatment for Patients with a Progressive Illness
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN109813916A (zh) * 2019-02-15 2019-05-28 浠思（上海）生物技术有限公司 利用HTRF一步法筛选Bcl-2家族成员之间结合的阻断剂的方法
JP7589159B2 (ja) 2019-02-26 2024-11-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP4168123B1 (en) * 2020-06-17 2025-08-27 University of Utah Research Foundation Biomarker based patient selection for proteasome inhibitor treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123791A2 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US20030073661A1 (en) * 2001-09-24 2003-04-17 Shigemi Matsuyama Method of modulating or examining Ku70 levels in cells
WO2004022580A2 (en) * 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
CN1302004C (zh) * 2003-08-22 2007-02-28 浙江海正药业股份有限公司 一种阿糖胞苷的制备方法
CN1981872B (zh) * 2005-12-12 2012-01-25 中国医学科学院肿瘤研究所 Puma在肿瘤放化疗增敏中的新用途
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
US8168755B2 (en) 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
MX2011008488A (es) * 2009-02-11 2011-10-24 Abbott Lab Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2.
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
EP2660746A1 (en) * 2012-04-30 2013-11-06 Royal College of Surgeons in Ireland Dose-response medical outcome model predictor system and method
WO2015010094A1 (en) * 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
WO2015066305A1 (en) * 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
US20180100859A1 (en) * 2015-03-24 2018-04-12 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123791A2 (en) 2006-03-31 2007-11-01 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
JP2009532033A (ja) 2006-03-31 2009-09-10 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 細胞の化学感受性を定量する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Thanh-Trang Thi Vo et al, Mitochondrial Priming Determines Chemotherapeutic Response in Acute Myeloid Leukemia, Harvard University (2012.04.05.), pp 1-109.
Triona Ni Chonghaile et al, Science(2011.11.25.), vol 334, pp 1129-1133.

Also Published As

Publication number Publication date
JP2018013498A (ja) 2018-01-25
EP2847592A4 (en) 2016-05-04
WO2013170176A3 (en) 2015-01-29
JP2015519565A (ja) 2015-07-09
JP6748050B2 (ja) 2020-08-26
EP2847592A2 (en) 2015-03-18
EP3236262B1 (en) 2019-09-25
EP3236262A3 (en) 2017-11-22
WO2013170176A2 (en) 2013-11-14
US20150301053A1 (en) 2015-10-22
CN107315088A (zh) 2017-11-03
HK1245888A1 (en) 2018-08-31
CN111856013A (zh) 2020-10-30
KR20150008177A (ko) 2015-01-21
EP3236262A2 (en) 2017-10-25
US20180246106A1 (en) 2018-08-30
CN104541170A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
KR102062416B1 (ko) 실용 가능한 암 진단 대체 법
US10624880B2 (en) Predicting response to alvocidib by mitochondrial profiling
US11519015B2 (en) Methods for determining chemosensitivity and chemotoxicity
US20200392585A1 (en) Context dependent diagnostics test for guiding cancer treatment
US20180100859A1 (en) Surrogate functional biomarker for solid tumor cancer
WO2015010094A1 (en) Differential bh3 mitochondrial profiling
HK1245888B (en) Surrogate functional diagnostics test for cancer
HK40022688B (en) Predicting response to alvocidib by mitochondrial profiling
HK40022688A (en) Predicting response to alvocidib by mitochondrial profiling
HK1228469A1 (en) Methods for determining chemosensitivity and chemotoxicity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231228

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000